logo
  Join        Login             Stock Quote

AMAG Pharma (AMAG) Submits Supplemental NDA For Iron Deficiency Anemia Therapy

 December 24, 2012 12:10 PM
 


(By Balaseshan) AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) said it has submitted a supplemental new drug application (sNDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use for inclusion of treating all iron deficiency anemia patients who cannot take oral iron.

The sNDA requests the U.S. Food and Drug Administration (FDA) approval to expand the indication for ferumoxytol beyond the current indication for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) to all adult patients with IDA who have failed or could not tolerate oral iron treatment.

The application includes data from two well-controlled phase 3 clinical trials of more than 1,400 patients. The sNDA submission is based on data from a global phase 3 program that evaluated the use of ferumoxytol in a broad range of adult IDA patients, all of whom had failed or could not tolerate oral iron treatment.

[Related -Six Stocks That Could Get An October Bump From The FDA]

More than 1,400 patients were enrolled in the two phase III clinical trials, IDA-301 (placebo comparator) and IDA-302 (active comparator). Both studies achieved their primary efficacy endpoints, with meaningful improvements in hemoglobin from baseline to the 35-day endpoint of the studies.

Adverse events and serious adverse events associated with IV iron therapy, including hypersensitivity reactions, were reported in both studies. No new safety signals, outside of those described in the current Feraheme label, were observed with ferumoxytol treatment in these studies. These clinical trials also included patient-reported outcomes data as pre-specified secondary and exploratory endpoints.

[Related -AMAG Pharma (AMAG): FDA Accepts Supplemental NDA For Iron Deficiency Anemia Therapy]

These outcomes endpoints, including quantitative measures of patients' fatigue and measures of quality of life, captured the negative pre-treatment impact anemia has on these patients' lives – and the significant improvement in these scores following a one gram course of therapy with ferumoxytol.

AMAG is trading down 0.79% at $15.03 on Monday. The stock has been trading between $12.43 and $19.62 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageHow the Chinese Slowdown Will Impact Your Investments

Most countries would find a quarterly growth rate of 7.3% a cause for a read on...

article imageHow To Profit From Foreign Investment In Real Estate

Though investors don't always capitalize on it, history has a way of repeating itself. In fact, when I saw read on...

article imageAnother Round Of Upbeat US Macro Reports

The US economy grew faster than expected in this year’s third quarter, according to this morning’s read on...

article imageDistinguishing The Fed's Securities Purchases From Monetary Expansion

There has been a bit of confusion about what today's FOMC announcement means with respect to Quantitative read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.